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ABSTRACT
Background Pseudodiastrophic dysplasia (PDD) is 
a severe skeletal dysplasia associated with prenatal 
manifestation and early lethality. clinically, PDD is 
classified as a ’dysplasia with multiple joint dislocations’; 
however, the molecular aetiology of the disorder is 
currently unknown.
Methods Whole exome sequencing (Wes) was 
performed on three patients from two unrelated families, 
clinically diagnosed with PDD, in order to identify the 
underlying genetic cause. The functional effects of the 
identified variants were characterised using primary cells 
and human cell- based overexpression assays.
Results Wes resulted in the identification of biallelic 
variants in the established skeletal dysplasia genes, 
B3GAT3 (family 1) and CANT1 (family 2). Mutations 
in these genes have previously been reported to cause 
’multiple joint dislocations, short stature, and craniofacial 
dysmorphism with or without congenital heart defects’ 
(’JDscD’; B3gaT3) and Desbuquois dysplasia 1 (canT1), 
disorders in the same nosological group as PDD. Follow- 
up of the B3GAT3 variants demonstrated significantly 
reduced B3gaT3/glcaT- i expression. Downstream in 
vitro functional analysis revealed abolished biosynthesis 
of glycosaminoglycan side chains on proteoglycans. 
Functional evaluation of the CANT1 variant showed 
impaired nucleotidase activity, which results in inhibition 
of glycosaminoglycan synthesis through accumulation of 
uridine diphosphate.
Conclusion For the families described in this study, 
the PDD phenotype was caused by mutations in the 
known skeletal dysplasia genes B3GAT3 and CANT1, 
demonstrating the advantage of genomic analyses 
in delineating the molecular diagnosis of skeletal 
dysplasias. This finding expands the phenotypic 
spectrum of B3gaT3- related and canT1- related skeletal 
dysplasias to include PDD and highlights the significant 
phenotypic overlap of conditions within the proteoglycan 
biosynthesis pathway.
InTRoduCTIon
Skeletal dysplasias are a group of over 450 different 
disorders which mainly affect bone and collagen 
development.1 2 While these disorders are individu-
ally rare, combined they affect 1 in 5000 births each 
year.3 The disease spectrum ranges from reduced 
bone growth resulting in shorter stature to severe 
developmental syndromes and perinatal lethality.1 4
One extremely rare skeletal dysplasia, at the 
severe end of the spectrum, is pseudodiastrophic 
dysplasia (PDD; MIM: 264180), which is associ-
ated with prenatal manifestation and early lethality. 
It is characterised by short- limbed short stature 
at birth, facial dysmorphism, and distinctive skel-
etal abnormalities including short ribs, mild to 
moderate platyspondyly, broad ilia with flaring, 
increased acetabular angle, shortened long bones 
with metaphyseal flaring, elongation of the prox-
imal and middle phalanges with subluxation of the 
proximal interphalangeal joints, subluxation of the 
elbow, and talipes equinovarus.5–11
While PDD shows phenotypic similarity to 
diastrophic dysplasia (MIM: 222600), there are key 
differences in the radiographic and chondro- osseous 
features,7 and further differences are also found at 
the molecular level. Diastrophic dysplasia has been 
shown to be caused by biallelic loss- of- function 
mutations in SLC26A2,12 13 but no likely causative 
variants have been identified in this gene in previ-
ously described cases of PDD.1 14 At present, the 
genetic basis of PDD remains unknown; however, 
as the disorder affects both males and females and 
has been observed to reoccur in families with unaf-
fected parents, an autosomal recessive inheritance 
is likely.7
Clinically, PDD is classified as part of the ‘dyspla-
sias with multiple joint dislocations’ subgroup, with 
the majority of these disorders caused by defects in 
proteoglycan (PG) biosynthesis.1 PGs are expressed 
on cellular surfaces and form a key component of 
extracellular matrices.15 16 They consist of a core 
protein, with covalently bound glycosaminoglycan 
(GAG) side chains. These polysaccharide side 
chains are classified based on the assembly of their 
disaccharide units, such as chondroitin sulfate (CS) 
and dermatan sulfate (DS). Since the extracellular 
matrices provide structure and stability for many 
tissues (ie, bone and cartilage), defects in enzymes 
involved in PG synthesis have a major impact on the 
development and assembly of skeletal and dermato-
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that result in enzymatic defects affecting biosynthesis of the PG’s 
GAG linker region are called ‘linkeropathies’.17 18
Aiming to identify the genetic cause of this extremely rare 
condition, PDD, we investigated four patients from two unre-
lated families clinically diagnosed with the disorder. Genomic 
analyses revealed mutations in two different established skeletal 
dysplasia genes. Functional validation with both primary cells 
and human cell- based overexpression assays demonstrated that 
PDD represents the most severe phenotypic presentation of 
defects in PG synthesis.
MeThodS
Study subjects
This study was performed as part of the National Health and 
Medical Research Council(NHMRC)- funded Genomic Autopsy 
Study, family study IDs: PED012 (family 1) and PED042 (family 
2).
Genetic analyses
Genomic DNA was isolated from whole blood (patients 1B, 2A 
and 2B, parental samples and unaffected siblings) or cultured 
chorion cells (patient 1A). DNA samples from patients 1A, 1B 
and 2B and their unaffected parents were submitted for whole 
exome sequencing (WES) at the Centre for Cancer Biology 
Australian Cancer Research Foundation(ACRF) Genomics 
Facility. Insufficient DNA was available for WES of patient 2A. 
Exonic sequences were enriched using the IDT xGen (family 1) 
or Roche NimbleGen SeqCap EZ MedExome (family 2) kit, and 
libraries were sequenced (100 bp (family 1) or 150 bp (family 2) 
paired- end reads) on an Illumina HiSeq (family 1) or NextSeq 
(family 2). Sequencing data were processed through a pipeline 
based on Picard, and alignment to the Human Genome Build 37 
(hg19) was performed using BWA. SNPs and small insertions/
deletions (indels) were called using GATK HaplotypeCaller 
V.3.4. Default filters were applied to variant calls using the 
GATK Variant Quality Score Recalibration approach. Candidate 
variants were confirmed and cosegregation assessed by Sanger 
sequencing of PCR- amplified genomic DNA from affected and 
unaffected family members.
Cell culture
Primary dermal fibroblasts were isolated from skin biopsies 
of patient 1A (16 weeks’ gestation) and gender and age- close 
controls (control 1: 11 weeks’ gestation; control 2: 21 weeks’ 
gestation). The biopsy was first cultured in Ham’s F10 medium 
(Gibco, Australia) with 20% fetal bovine serum and 1% Penicillin- 
Streptomycin (both Sigma- Aldrich, Australia) at 36.6°C, with 
5% CO2. Once established, the fibroblasts were cultured in Basal 
Eagle’s Medium 1X (Gibco) with 10% fetal bovine serum and 
2 mM L- glutamine (both Sigma- Aldrich).
Generation of recombinant protein
Wild- type human B3GAT3 expression vector was generated as 
described previously.19 In brief, a truncated form of wild- type 
B3GAT3, lacking the first 43 amino acids, was amplified from 
human placenta cDNA and inserted into a p3XFLAG- CMV8 
vector (Sigma, St Louis, Missouri). Wild- type human CANT1 
expression vector was constructed as previously described, 
with slight modifications.20 Briefly, a truncated form of wild- 
type CANT1, lacking the first 64 amino acids (including the 
predicted transmembrane domain), was amplified from human 
placenta cDNA (Clontech, Mountain View, California). The 
DNA fragment was subcloned into a p3xFLAG- CMV8 vector, 
resulting in the fusion of CANT1 to the preprotrypsin leader 
sequence and the 3xFLAG tag sequence at the N- terminus of 
the vector. Mutant vectors (containing B3GAT3: Arg169Trp and 
Arg225*; CANT1: Glu215Lys) were constructed by overlapping 
extension PCR and mutations confirmed by sequence analysis.
B3GAT3 and CANT1 (wild- type and mutant) vectors were then 
transiently transfected into HEK293T cells using the FuGENE 
HD DNA Transfection Reagent (Promega). For B3GAT3, 3 days 
after transfection, cells were collected and lysed with mamma-
lian protein extraction reagent (M- PER, ThermoFisher Scien-
tific) and lysates incubated with anti- FLAG affinity agarose 
resin (Wako, Osaka, Japan) for 1–4 hours at 4°C. For CANT1, 
3 days after transfection, aliquots of the conditioned media were 
incubated with anti- FLAG M2 agarose resin (Sigma) for 2 hours 
at 4°C. To examine the expression of recombinant enzymes, 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blotting (online supplementary figure 
S1) were performed using either an anti- FLAG antibody (Wako) 
(B3GAT3) or an anti- FLAG M2 antibody (Sigma) (CANT1).
Glucuronyltransferase activity assay
The effect of each B3GAT3 variant (Arg169Trp and Arg225*) 
on the glucuronyltransferase activity of B3GAT3/GlcAT- I was 
examined as previously described.19 In brief, the resin- bound 
enzyme from the cell lysate, uridine diphosphate-14C- labelled 
glucuronic acid (UDP-[14C]GlcA, PerkinElmer) and galactoseβ1- 
3galactoseβ1- O- methyl (Galβ1- 3Galβ1- O- Me, Sigma) were 
used as the enzyme source, the donor substrate and the acceptor 
substrate, respectively. The reaction mixture was incubated 
for 4 hours at 37°C (HEK293T) or 30°C (fibroblasts). Radio-
labelled products were separated from UDP-[14C]GlcA using 
anion- exchange resin, AG 1- X8 (PO4
2− form), as described 
previously.21 The separated products, [14C]GlcAβ1- 3Galβ1- 
3Galβ1- O- Me, were quantified by a liquid scintillation counter 
(LSC-7400, Aloka).
Biosynthesis of GAG side chains
The impact of the B3GAT3 variants (Arg169Trp and Arg225*) 
on the function of B3GAT3/GlcAT- I in the biosynthesis of disac-
charide units was investigated using cell- based ELISA (In- Cell 
ELISA). As described previously,22 CS and DS chains on the cell 
surface and extracellular matrix were compared between fibro-
blasts from patient 1A and control subjects. Briefly, fibroblasts 
were cultured in 96- well plates (5000 cells/well) for 1 day. Cells 
were washed and treated with chondroitinase ABC (Seikagaku) 
at 37°C for 30 min, before being fixed and incubated with the 
primary antibodies, a mixture of anti- CS- stub antibodies (1B5, 
2B6 and 3B3) (Cosmo Bio, Tokyo). Cells were then incubated 
with the secondary antibody, alkaline phosphatase- conjugated 
anti- mouse IgG, before finally being incubated with the substrate, 
p- nitrophenyl phosphate, and analysed by measuring the absor-
bance at 405 nm with an iMark Microplate Absorbance Reader 
(Bio- Rad).
nucleotidase activity assay
The effect of the CANT1 variant (Glu215Lys) on the nucleoti-
dase activity of CANT1 towards uridine diphosphate (UDP) was 
examined, similar to previously described.20 In brief, the assay 
mixture contained 5 µL of 10- times diluted conditioned media, 
50 mM 2-(N- morpholino) ethanesulfonic acid- NaOH (pH 6.5), 
and 1 mM CaCl2, with 0.2 mM UDP (Promega) as the substrate, 
in a total volume of 50 µL. The mixture was incubated at 37°C 
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Figure 1 The pedigrees and the presence of mutations in two unrelated families with pseudodiastrophic dysplasia. (a) B3GAT3 mutations in a non- 
consanguineous australian family with two affected siblings. (B) CANT1 mutations in a consanguineous Turkish family with two affected siblings.
determine the amount of unreacted UDP, the reaction product 
was mixed with the UDP detection reagent, containing an 
enzyme to convert UDP to ATP (UDP- Glo Glycosyltransferase 
Assay Kit, Promega). The resultant ATP was measured using a 
luciferase/luciferin reaction and the luminescent signals detected 
using a Victor X4 luminometer (PerkinElmer).
ReSulTS
Clinical description
Patients 1A and 1B of family 1 were born to a non- 
consanguineous couple with three healthy children (two male, 
one female), described previously11 (figure 1A). Patient 1A was 
male, stillborn at 16 weeks’ gestation after an uneventful first 
trimester. Autopsy revealed an oedematous, growth- restricted, 
dysmorphic fetus with cleft palate, abdominal distension, intes-
tinal malrotation, anorectal dysgenesis, absent external genitalia, 
and renal system anomalies including enlarged bladder with no 
outlet, absent left kidney, and right kidney with reduced nephron 
number and tortuous ureter. The skeletal phenotype included 
bowed and shortened limbs (especially of the radii, ulnae and 
femora), short ribs, platyspondyly, small sacrum, reduced ossi-
fication of the pubic bones and cervical vertebral segments, and 
talipes equinovarus (figure 2A).
Patient 1B was female, live- born at 37+5 weeks’ gestation 
after induction of labour for polyhydramnios. Antenatal ultra-
sound at 13 weeks’ gestation showed raised nuchal translucency 
of 4.7 mm, oedema and short femur lengths, which persisted 
in subsequent scans. Bowing of the long bones was prominent. 
The postnatal phenotype included generalised micromelia, 
joint contractures and facial dysmorphism with midface hypo-
plasia, small upturned nose, micrognathia, small mouth, and 
cleft palate (figure 2B). Several bilateral anterior polar cataracts 
were also identified. The distinctive skeletal phenotype included 
mild platyspondyly, kyphosis, flared ilia, short long bones with 
metaphyseal flaring, short and broad metacarpals and phalanges, 
bilateral equinovarus deformity, and multiple joint dislocations 
(figure 2B,C). These findings were clinically consistent with 
PDD and allowed retrospective diagnosis of the disorder in 
patient 1A. Following respiratory distress, patient 1B required 
invasive ventilation and prolonged intensive care; however, care 
was withdrawn and the patient was deceased at 9 months of age.
Patients 2A and 2B of family 2 were born to a consanguin-
eous Turkish couple (figure 1B). Patient 2A was male, born at 
40 weeks’ gestation after an uneventful pregnancy. Antenatal 
ultrasonography showed short long bones and increased nuchal 
thickness. Postnatally, he appeared hydropic with relative macro-
cephaly, prominent eyes, depressed nasal bridge, small nose, 
midface hypoplasia, small mouth and a short neck (figure 2E). 
He had a narrowed thorax and prominent abdomen, short 
extremities, over- riding and flexion contracture of the fingers, 
postaxial polydactyly on the right hand, and bilateral talipes equi-
novarus (figure 2E). Postnatal skeletal survey showed shortened 
long bones with mild bowing and widened metaphyses, medial 
metaphyseal beaking of the proximal femora, steep acetabular 
angle, and multiple joint dislocations (figure 2F). Abdominal 
ultrasonography was normal. Echocardiography showed ventric-
ular septal defect, secundum atrial septal defect and right- sided 
arcus aorta. The patient was deceased at 6 months of age due to 
respiratory insufficiency, secondary to pneumonia.
Patient 2B was also male, terminated at 18 weeks’ gestation 
after detection of similar manifesting features on ultrasound. 
Postmortem examination reported hydropic appearance, midface 
hypoplasia, narrow bell- shaped thorax, short limbs, camptodac-
tyly and equinovarus deformity. Salient skeletal features included 
shortened long bones, multiple joint dislocations, short metacar-
pals and malaligned short phalanges (figure 2D). These findings 
led to a clinical diagnosis of PDD in both affected siblings.
Identification of candidate variants
Proband- parent (quad and trio) WES was employed on families 
1 and 2, respectively, resulting in an average coverage of 66x 
(patient 1A), 70x (patient 1B) and 124x (patient 2B), with 83% 
(patient 1A), 85% (patient 1B) and 94% (patient 2B) of targeted 
bases being covered by at least 20 reads (online supplementary 
table S1).
For family 1, a total of 83 395 (patient 1A) and 82 257 (patient 
1B) variants were detected in the WES data. Filtering for rare 
(<1%), non- synonymous variants resulted in 383 (patient 1A) 
and 297 (patient 1B) variants. No overlapping homozygous 
variants were identified. However, overlapping compound 
heterozygous variants were identified in three genes (SPEG, 
EID3 and B3GAT3). Of these three genes, only mutations in 
B3GAT3 are known to cause skeletal dysplasia. B3GAT3 encodes 
for beta-1,3- glucuronyltransferase 3 (GlcAT- I), and mutations 
in this gene are known to cause ‘multiple joint dislocations, 
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Figure 2 clinical and radiographic phenotype of siblings from two unrelated families with pseudodiastrophic dysplasia. (a,D) skeletal phenotype of 
patient 1a (a) and patient 2B (D) at 16 and 18 weeks’ gestation, respectively. Both fetuses appeared hydropic with shortened and bowed long bones, 
metaphyseal flaring, multiple joint dislocations, flared iliac wings, hypoplastic distal ilia, and talipes equinovarus. (B,e) clinical phenotype during infancy 
of patient 1B (B) and patient 2a (e). Both infants displayed relative macrocephaly, short neck, micromelia, short stature, multiple large joint subluxations, 
interphalangeal dislocation and deviation, and talipes equinovarus. Facial gestalt included round face and full cheeks, prominent eyes, depressed nasal 
bridge with small anteverted nose, small mouth, and micrognathia. (c,F) skeletal phenotype during infancy of patient 1B (c) and patient 2a (F). Both infants 
showed shortened and mildly bowed long bones, with widened metaphyses. Patient 1B also displayed platyspondyly, thoracic kyphosis, and broad and flared 
ilia. Patient 2a also showed a narrowed thorax, steep acetabular angle and medial metaphyseal beaking of the proximal femora. (a,c) republished with 
permission from Yap et al.11 (B) republished with permission from spranger et al.40
congenital heart defects’ (JDSCD (MIM: 245600); formerly 
Larsen syndrome).19 Segregation analysis by Sanger sequencing 
confirmed both B3GAT3 variants to be present in compound 
heterozygosity in the two affected patients. The maternal 
variant, p.Arg225* (Chr11(GRCh37):g.62384214G>A, 
NM_012200.3:c.673C>T), and the paternal variant, p.Ar-
g169Trp (Chr11(GRCh37):g.62384572G>A, NM_012200.3 
:c.505C>T), were confirmed as heterozygous. Only the paternal 
variant was present in the two unaffected brothers, with the 
unaffected sister carrying neither variant (figure 1A).
Both B3GAT3 variants are rare in the population data-
base gnomAD and have never been observed in homozygosity 
(Arg225*: 4 alleles, 0.001%; Arg169Trp: 3 alleles, 0.001%).23 
The Arg225* nonsense variant is predicted to lead to a truncated 
or absent protein. The variant has been reported once in ClinVar 
as likely pathogenic, but no functional evidence was provided, 
and the zygosity and phenotype associated with the variant were 
not documented (VCV000620480.1). The novel Arg169Trp 
missense variant is predicted to be deleterious by multiple lines 
of computational evidence, with Arg169 being highly conserved 
(97 of 99 species).
For family 2, patient 2B, a total of 94 047 variants were 
detected in the WES data. Filtering for rare (<1%), non- 
synonymous, homozygous variants resulted in 24 variants. Only 
one of these variants affected a gene (CANT1) which has been 
associated with a skeletal dysplasia phenotype. CANT1 encodes 
for the enzyme calcium- activated nucleotidase 1, and mutations 
in CANT1 are associated with Desbuquois dysplasia 1 (DBQD1; 
MIM: 251 450).24 No compound heterozygous variants were 
identified in genes associated with other skeletal dysplasias. 
Segregation analysis by Sanger sequencing showed the CANT1 
variant, p.Glu215Lys (Chr17(GRCh37):g.76991292C>T, 
NM_138793.3:c.643G>A), was also present in homozygosity 
in patient 2A, confirming segregation with disease. Both parents 
carried the variant in heterozygosity (figure 1B).
The Glu215Lys missense variant has not been reported before 
in association with disease, but is rare in the population data-
base gnomAD (1 allele, 0.0004%).23 Glu215 is highly conserved 
(92 of 92 species) and multiple lines of computational evidence 
predict the variant to be damaging.
Glucuronyltransferase activity
The effect of the B3GAT3 variants (identified in family 1) on 
glucuronyltransferase activity was assessed using lysates from 
transiently transfected HEK293T cells and primary fibroblasts. 
UDP-[14C]GlcA and Galβ1- 3Galβ1- O- methyl were used as the 
donor and acceptor substrates, respectively. This assay revealed 
significantly (p<0.0002, Student’s t- test) decreased enzymatic 
activity in recombinant Arg169Trp B3GAT3/GlcAT- I HEK293T 
cell lysates compared with wild- type cell lysates. Lysates from 
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Figure 3 The functional effect of the identified B3GAT3 and 
CANT1 mutations. (a) glucuronyltransferase activity of recombinant 
B3gaT3/glcaT- i from cell lysates of heK293T cells. enzyme activity is 
significantly decreased for the arg169Trp mutant protein compared with 
wild- type protein, and is absent for the arg225* mutant protein. (B) 
glucuronyltransferase activity in fibroblast cell lysates from patient 1a 
and gender and age- close healthy controls. enzyme activity is significantly 
reduced in patient cells compared with controls. (c) in- cell elisa result 
comparing cs/Ds chains on the cell surface and extracellular matrix of 
fibroblasts from patient 1a and gender and age- close healthy controls. cs/
Ds- stub antibodies are markedly reduced in patient cells compared with 
controls. (D) nucleotidase activity of the recombinant canT1 expressed in 
heK293T cells. enzyme activity is significantly decreased for the glu215lys 
mutant protein compared with wild- type protein. *P<0.01, **P<0.001, 
***P<0.0002, ****P<0.0001. cs, chondroitin sulfate; Ds, dermatan 
sulfate; UDP, uridine diphosphate.
no enzymatic activity (p<0.0001, Student’s t- test) (figure 3A). 
Similarly, lysates from patient 1A fibroblasts showed signifi-
cantly (p<0.001, Student’s t- test) reduced glucuronyltrans-
ferase activity compared with lysates from control fibroblasts 
(figure 3B). These results suggest that both variants are severe 
loss- of- function mutations and confirm that the truncated 
Arg225* mutant protein is functionally null.
Biosynthesis of GAG side chains
The functional impact of the B3GAT3 variants on the biosyn-
thesis of GAG side chains was investigated by analysing CS and 
DS using a cell- based ELISA (In- Cell ELISA) assay. This exper-
iment revealed markedly (p<0.01, Student’s t- test) reduced 
CS/DS- stub antibodies in patient 1A fibroblasts compared with 
controls (figure 3C), indicating a markedly decreased number 
of CS and DS chains on the cell surface and in the extracel-
lular matrix of patient cells. Taken together with the results of 
the enzyme activity assay, this indicates that the mutations in 
B3GAT3 affect glucuronyltransferase activity, leading to a defect 
in the biosynthesis of GAGs and/or their PGs in the patients.
CAnT1 enzymatic activity
The effect of the CANT1 variant (identified in family 2) on 
nucleotidase activity was evaluated using recombinant protein 
obtained from conditioned media of transiently transfected 
HEK293T cells, with UDP used as the substrate. This assay 
revealed that although the expression levels of wild- type and 
mutant enzyme in the conditioned media were comparable 
(online supplementary figure S1B), the enzymatic activity of 
recombinant mutant CANT1 (Glu215Lys) was significantly 
(p<0.0001, Student’s t- test) reduced compared with that of 
wild- type enzyme (figure 3D). This result suggests the variant to 
be a severe loss- of- function mutation.
dISCuSSIon
PDD is known to be an extremely rare disorder at the severe 
end of the phenotypic spectrum for skeletal dysplasias and is 
associated with prenatal- onset manifestation and early lethality.7 
Considering the lethality, the disorder was long expected to result 
from a genetic defect in an unidentified disease gene. Aiming to 
identify this gene and characterise the genetic mutations under-
lying PDD, we performed exome sequencing on DNA samples 
from two families (family 1: quad; family 2: trio). Unexpect-
edly, our genomic analysis revealed mutations in known OMIM 
genes, B3GAT3 (family 1) and CANT1 (family 2), associated 
with two different skeletal dysplasias. Consistent with the func-
tion of genes causative for other skeletal disorders in the same 
classification subgroup as PDD, both of these genes are involved 
in PG synthesis.1
B3GAT3 (GlcAT- I) deficiency is characterised by a defect in 
glucuronyltransferase activity, resulting in defective biosynthesis 
of the GAG linker region of PGs.19 Specifically, B3GAT3/GlcAT- I 
is responsible for the transfer of a GlcA residue from UDP- GlcA 
to the last of the four saccharides of the linker region.25 Bial-
lelic B3GAT3 mutations are known to cause a skeletal dysplasia 
phenotype, JDSCD, characterised by shortened and bowed long 
bones, spine curvatures, and foot deformities. Other common 
features include facial dysmorphism, joint dislocation, congenital 
cardiac defects, joint contractures and bone fragility.16 18 19 22 26–31 
Lethality before the age of 1 year has also been reported.29 30 The 
majority of these clinical manifestations were observed in the 
affected individuals of family 1 and have also been reported in 
other patients with PDD,5–10 highlighting the extensive pheno-
typic similarities between PDD and B3GAT3- related disease. 
Prenatal detection of bowed long bones may be an early indica-
tion of a severe B3GAT3- related disorder, like PDD.
The varied clinical spectrum of B3GAT3- associated disease is 
possibly explained by mutation- specific levels of residual enzyme 
activity.30 We therefore performed functional assays to evaluate 
the downstream effect of the identified variants in B3GAT3. For 
both variants (Arg169Trp and Arg225*), cell lysates from recom-
binant HEK293T cells showed a near- complete or complete 
loss of enzyme activity in vitro, respectively (figure 3A). Simi-
larly, the patient fibroblasts showed severely diminished glucu-
ronyltransferase activity and a reduction of CS and DS chains 
(figure 3B,C). While these experiments provide the required 
functional evidence to confirm that the B3GAT3 mutations are 
the cause of skeletal dysplasia in family 1, simultaneous testing 
of patient fibroblasts from patients with PDD and JDSCD will 
be required to elucidate genotype–phenotype correlations. 
However, due to early lethality of PDD and the rarity of both 
disorders, this might not be feasible.
The CANT1 nucleotidase is known to hydrolyse UDP, a 
product of glycosyltransferase reactions.20 Functional defects in 
CANT1 result in impaired removal of UDP, leading to UDP accu-
mulation and inhibition of glycosyltransferase activities, thereby 
limiting GAG synthesis.32 Biallelic mutations in CANT1 are asso-
ciated with DBQD1, which is characterised by prenatal- onset 
































enet: first published as 10.1136/jm




459Byrne AB, et al. J Med Genet 2020;57:454–460. doi:10.1136/jmedgenet-2019-106700
Genotype- phenotype correlations
advanced carpal ossifications. Additional features can include 
facial dysmorphism, congenital cardiac defects and talipes 
equinovarus,24 32–38 again overlapping closely with many of the 
features observed in patients with PDD.5–10 Interestingly, several 
of the earlier described CANT1 patients also died perinatally or 
during early infancy.24 32 Following the identification of CANT1 
as the molecular basis of the PDD phenotype in family 2, the 
subtle presence of monkey- wrench femoral neck in patient 2A 
was retrospectively considered consistent with CANT1- related 
disease.
CANT1 mutations have also been identified as causative of a 
relatively milder skeletal disorder, multiple epiphysial dysplasia 7 
(MED7; MIM 617719), characterised by short stature and early- 
onset osteoarthrosis.39 Functional assessment of these MED7- 
linked mutations, in parallel with DBQD1 and PDD mutations, 
will be important for understanding the mechanistic basis of 
the described allelic heterogeneity. Similar to an earlier study, 
we assessed the functional effect of the variant we identified in 
CANT1 by measuring its activity towards UDP.34 The recombi-
nant mutant CANT1 (Glu215Lys) expressed in HEK293T cells 
showed defective nucleotidase activity, with close to complete 
loss of function (figure 3D).
In conclusion, we describe four patients from two families 
with a clinical diagnosis of PDD and mutations in known genes 
involved in skeletal dysplasias (B3GAT3 and CANT1). Functional 
assays confirmed causality of the mutations and support previ-
ously published functional data which suggest that a complete 
loss of function is responsible for the severe, lethal pheno-
type observed in our patients. We propose that PDD is likely 
not a separate genetic disorder, but rather may be considered 
the most severe phenotypic manifestation of skeletal dysplasia 
arising from defects in PG biosynthesis. This finding highlights 
the clinical challenge in differentiating PDD from other skeletal 
dysplasias, such as B3GAT3- associated and CANT1- associated 
disorders, due to significant phenotypic overlaps. A genomics- 
first approach, like exome sequencing, may therefore be a valu-
able tool in delineating the molecular defects underlying skeletal 
dysplasias and will aid in nosology and characterising the subtle 
phenotypic heterogeneity within this group of disorders.
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